Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2015 Sep;22(9):946-9.
doi: 10.1097/GME.0000000000000445.

Long-term follow-up of bone density in women with primary ovarian insufficiency

Affiliations

Long-term follow-up of bone density in women with primary ovarian insufficiency

Cristina Laguna Benetti-Pinto et al. Menopause. 2015 Sep.

Abstract

Objective: This study aims to analyze long-term variation in bone mineral density among young women with primary ovarian insufficiency.

Methods: A cohort study evaluated bone mineral density in 72 women with primary ovarian insufficiency who were receiving estrogen + progestogen therapy. Bone mineral density was evaluated every 2 years for 8 years.

Results: The women were young, with a mean (SD) age of 34.1 (6.7) years and had a bone density measurement at baseline. The mean (SD) time between the last menstruation and the beginning of hormone treatment was 2.9 (4.2) years. The initial mean (SD) bone mineral density was 1.03 (0.17) and 0.91 (0.16) g/cm for the lumbar spine and femoral neck, respectively. The mean (SD) T score was -1.03 (1.39) and -0.29 (1.09) for the lumbar spine and femoral neck, respectively. Bone mineral density measurements after a follow-up period of 2, 4, 6, and 8 years did not differ from bone mineral density at baseline. Osteopenia and osteoporosis were observed at the lumbar spine and femoral neck in 46% and 25% of women at the time of diagnosis, with no difference in the percentage of affected women across time.

Conclusions: Although women with primary ovarian insufficiency who are receiving estrogen + progestogen therapy maintain stable bone mass throughout an 8-year follow-up period, this treatment is not sufficient to decrease the number of women who experience some level of low bone density. Therapeutic regimens should be reviewed, probably with resumption of discussions about the need for other therapeutic strategies.

PubMed Disclaimer

Comment in

Similar articles

Cited by

Publication types

LinkOut - more resources